Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial

被引:135
作者
Levy, Y [1 ]
Capitant, C
Houhou, S
Carriere, I
Viard, JP
Goujard, C
Gastaut, JA
Oksenhendler, E
Boumsell, L
Gomard, E
Rabian, C
Weiss, L
Guillet, JG
Delfraissy, JF
Aboulker, JP
Seligmann, M
机构
[1] Hop Henri Mondor, Unite Immunol Clin, F-94010 Creteil, France
[2] INSERM, Villejuif, France
[3] ANRS, Study Grp 048, Paris, France
关键词
D O I
10.1016/S0140-6736(98)07345-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Intermittent interleukin-2 therapy for HIV-l by continuous intravenous infusion leads to sustained increase of CD4 T cells. This method of administration is, however, inconvenient and has limiting toxic effects. We did a randomised study to compare safety and efficacy of antiviral treatment alone or combined with various interleukin-2 regimens in HIV-1-infected patients. Methods. 94 symptom-free patients, naive to antiretroviral treatment, with CD4-T-cell counts of 250-550 cells/mu l at baseline were randomly assigned zidovudine and didanosine alone (n = 26) or combined with interleukin-2 administered intravenously (12 million IU/day, n = 22) or subcutaneously (3 million IU/m(2) twice daily, n = 24) for 5 days, or were given polyethyleneglycol-modified (PEG) interleukin-2 (2 million IU/m(2) intravenous bolus, n = 22) administered every 2 months from week 2 to week 50 (seven cycles). Safety and immunological and virological results were monitored until week 56. Findings. CD4-T-cell count increased to higher than baseline by a mean of 564 cells/mu L (subcutaneous group), 676 cells/mu L (intravenous group), 105 cells/mu L (PEG group), and 55 cells/mu L (antiretroviral-therapy group, p = 0.0001). 68% and 77% of patients in the subcutaneous and intravenous; groups, respectively, achieved an 80% increase of CD4 T cells (p < 0.001). In these two groups, 50% of patients restored a CD4/CD8-T-cell ratio of more than 1. The groups did not differ significantly for changes in plasma HIV-1 RNP, loads throughout the study. The duration of common side-effects of interleukin-2 was shorter in the subcutaneous group, which enabled outpatient treatment. Naive and memory CD4 T cells, CD28 expression on CD4 and CD8 T cells, and restoration of in-vitro proliferative response to mitogens and recall antigens increased in the intravenous and subcutaneous groups. Interpretation. Subcutaneous interleukin-2 is a convenient regimen that, as well as intravenous therapy, improves immunological function in HIV-l-infected patients receiving two nucleosides. Larger studies are needed to show whether immunological improvements translate into clinical benefit.
引用
收藏
页码:1923 / 1929
页数:7
相关论文
共 24 条
[11]   Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV plus subjects [J].
De Paoli, P ;
Zanussi, S ;
Simonelli, C ;
Bortolin, MT ;
D'Andrea, M ;
Crepaldi, C ;
Talamini, R ;
Comar, M ;
Giacca, M ;
Tirelli, U .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2737-2743
[12]   Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir [J].
Kelleher, AD ;
Carr, A ;
Zaunders, J ;
Cooper, DA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) :321-329
[13]   Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus [J].
Kovacs, JA ;
Vogel, S ;
Albert, JM ;
Falloon, J ;
Davey, RT ;
Walker, RE ;
Polis, MA ;
Spooner, K ;
Metcalf, JA ;
Baseler, M ;
Fyfe, G ;
Lane, HC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (18) :1350-1356
[14]   INCREASES IN CD4 T-LYMPHOCYTES WITH INTERMITTENT COURSES OF INTERLEUKIN-2 IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PRELIMINARY-STUDY [J].
KOVACS, JA ;
BASELER, M ;
DEWAR, RJ ;
VOGEL, S ;
DAVEY, RT ;
FALLOON, J ;
POLIS, MA ;
WALKER, RE ;
STEVENS, R ;
SALZMAN, NP ;
METCALF, JA ;
MASUR, H ;
LANE, HC .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (09) :567-575
[15]   Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease [J].
Li, TS ;
Tubiana, R ;
Katlama, C ;
Calvez, V ;
Ait Mohand, H ;
Autran, B .
LANCET, 1998, 351 (9117) :1682-1686
[16]   NEW CONCEPTS IN THE IMMUNOPATHOGENESIS OF HIV-INFECTION [J].
PANTALEO, G ;
FAUCI, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1995, 13 :487-512
[17]   Decay characteristics of HIV-1-infected compartments during combination therapy [J].
Perelson, AS ;
Essunger, P ;
Cao, YZ ;
Vesanen, M ;
Hurley, A ;
Saksela, K ;
Markowitz, M ;
Ho, DD .
NATURE, 1997, 387 (6629) :188-191
[18]   Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia [J].
Rosenberg, ES ;
Billingsley, JM ;
Caliendo, AM ;
Boswell, SL ;
Sax, PE ;
Kalams, SA ;
Walker, BD .
SCIENCE, 1997, 278 (5342) :1447-1450
[19]   Lymphocytes subsets in normal individuals: Analysis by four color immunofluorescence and flow cytometry on whole blood [J].
Schiavon, V ;
Roth, P ;
Bolton, WE ;
Farcet, JP ;
Bensussan, A ;
Boumsell, L .
TISSUE ANTIGENS, 1996, 48 (4-I) :312-318
[20]   INTERLEUKIN-2 - INCEPTION, IMPACT, AND IMPLICATIONS [J].
SMITH, KA .
SCIENCE, 1988, 240 (4856) :1169-1176